ADPT
Income statement / Annual
Last year (2023), Adaptive Biotechnologies Corporation's total revenue was $170.28 M,
a decrease of 8.11% from the previous year.
In 2023, Adaptive Biotechnologies Corporation's net income was -$225.25 M.
See Adaptive Biotechnologies Corporation,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
Operating Revenue |
$170.28 M |
$185.31 M |
$154.34 M |
$98.38 M |
$85.07 M |
$55.66 M |
$38.45 M |
Cost of Revenue |
$75.55 M
|
$57.91 M
|
$49.30 M
|
$22.53 M
|
$22.27 M
|
$19.67 M
|
$15.68 M
|
Gross Profit |
$94.72 M
|
$127.40 M
|
$105.04 M
|
$75.85 M
|
$62.80 M
|
$36.00 M
|
$22.77 M
|
Gross Profit Ratio |
0.56
|
0.69
|
0.68
|
0.77
|
0.74
|
0.65
|
0.59
|
Research and Development Expenses |
$122.12 M
|
$141.76 M
|
$142.34 M
|
$116.07 M
|
$70.71 M
|
$39.16 M
|
$32.00 M
|
General & Administrative Expenses |
$83.93 M
|
$88.53 M
|
$74.50 M
|
$49.54 M
|
$30.33 M
|
$20.41 M
|
$15.95 M
|
Selling & Marketing Expenses |
$88.58 M
|
$95.60 M
|
$95.47 M
|
$61.36 M
|
$38.45 M
|
$24.49 M
|
$16.77 M
|
Selling, General & Administrative Expenses |
$172.51 M
|
$184.13 M
|
$169.97 M
|
$110.89 M
|
$68.79 M
|
$44.90 M
|
$32.71 M
|
Other Expenses |
$27.13 M
|
$1.70 M
|
$1.70 M
|
$1.70 M
|
$1.70 M
|
$1.70 M
|
$1.69 M
|
Operating Expenses |
$321.76 M
|
$327.59 M
|
$314.01 M
|
$228.67 M
|
$141.19 M
|
$85.75 M
|
$66.40 M
|
Cost And Expenses |
$397.31 M
|
$385.49 M
|
$363.31 M
|
$251.20 M
|
$163.46 M
|
$105.42 M
|
$82.08 M
|
Interest Income |
$15.53 M
|
$4.06 M
|
$1.67 M
|
$6.59 M
|
$9.79 M
|
$3.31 M
|
$1.64 M
|
Interest Expense |
$13.80 M
|
$4.24 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Depreciation & Amortization |
$22.23 M
|
$28.15 M
|
$20.98 M
|
$11.74 M
|
$7.79 M
|
$6.00 M
|
$5.80 M
|
EBITDA |
-$189.27 M |
-$167.98 M |
-$193.35 M |
-$144.35 M |
-$70.60 M |
-$43.76 M |
-$37.84 M |
EBITDA Ratio |
-1.11
|
-1.05
|
-1.34
|
-1.54
|
-0.9
|
-0.79
|
-0.96
|
Operating Income Ratio |
-1.33
|
-1.08
|
-1.35
|
-1.55
|
-0.92
|
-0.89
|
-1.16
|
Total Other Income/Expenses Net |
$1.73 M
|
-$182,000.00
|
$1.67 M
|
$6.59 M
|
$9.79 M
|
$3.31 M
|
$1.64 M
|
Income Before Tax |
-$225.30 M
|
-$200.37 M
|
-$207.30 M
|
-$146.23 M
|
-$68.61 M
|
-$46.45 M
|
-$42.83 M
|
Income Before Tax Ratio |
-1.32
|
-1.08
|
-1.34
|
-1.49
|
-0.81
|
-0.83
|
-1.11
|
Income Tax Expense |
$0.00
|
-$57.90 M
|
-$1.69 M
|
-$6.59 M
|
-$9.79 M
|
$3.31 M
|
-$804,000.00
|
Net Income |
-$225.25 M
|
-$142.46 M
|
-$205.61 M
|
-$139.64 M
|
-$58.82 M
|
-$46.45 M
|
-$42.83 M
|
Net Income Ratio |
-1.32
|
-0.77
|
-1.33
|
-1.42
|
-0.69
|
-0.83
|
-1.11
|
EPS |
-1.56 |
-1 |
-1.46 |
-1.06 |
-0.85 |
-0.44 |
-0.41 |
EPS Diluted |
-1.56 |
-1 |
-1.46 |
-1.06 |
-0.85 |
-0.44 |
-0.41 |
Weighted Average Shares Out |
$144.38 M
|
$142.52 M
|
$140.35 M
|
$131.22 M
|
$69.17 M
|
$105.43 M
|
$105.43 M
|
Weighted Average Shares Out Diluted |
$144.38 M
|
$142.52 M
|
$140.35 M
|
$131.22 M
|
$69.17 M
|
$105.43 M
|
$105.43 M
|
Link |
|
|
|
|
|
|
|